Interleukin-1 (IL-1) has been implicated in the disease progression of multiple sclerosis (MS). In the animal model of MS, experimental autoimmune encephalomyelitis (EAE), the induction of disease is significantly attenuated in mice lacking the type I IL-1 receptor (IL-1R1). In this study, we created a transgenic mouse (eIL-1R1 kd) in which IL-1R1 expression is knocked down specifically in endothelial cells. Induction of EAE in eIL-1R1 kd mice results in a decrease in incidence, severity and delayed onset of EAE. In addition, eIL-1R1 kd mice show significant decrease in VCAM-1 expression and diminished CD45 + and CD3 + infiltrating leukocytes in the spinal cord in animals challenged with EAE. Further, IL-1 and IL-23 stimulate IL-17 production by splenocytes from both wild type and the eIL-1R1 kd animals. Similarly, IL-1 and IL-23 synergistically stimulate splenocytes proliferation in these two strains of animals. After immunization with MOG 79-96 , although eIL-1R1 kd mice displayed greatly reduced clinical scores, their splenocytes produced IL-17 and proliferated in response to a second MOG challenge, similar to wild type animals. These findings indicate a critical role for endothelial IL-1R1 in mediating the pathogenesis of EAE, and describe a new model that can be used to study endothelial IL-1R1.
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Introduction
Interleukin-1 (IL-1) is an important cytokine in inflammation and immunoregulation (Dinarello, 2009) . Its relevance in multiple sclerosis (MS) has been amply demonstrated. Gene polymorphisms (Dincic et al., 2006) and/or dysregulated levels of IL-1, changes in the receptor for IL-1 (IL-1R) and changes in the naturally produced IL-1 receptor antagonist (IL-1Ra) have all been implicated in the pathology of MS. For example, elevated levels of IL-1b levels have been found in the white matter and in acute lesions (Brosnan et al., 1995) , cerebrospinal fluid, and sera (Hauser et al., 1990; Tsukada et al., 1991) of MS patients. In addition, microglial cells as well as hematogenous macrophages entering the central nervous system (CNS) in patients with MS secrete high levels of IL-1b (Cannella and Raine, 1995) . An increased risk of MS has also been observed in families that have higher production ratios of IL-1b over its naturally occurring IL-1Ra (Ahmed et al., 2002) . In general, increased IL-1 activity is associated with more severe MS symptoms.
In the animal model of MS, experimental autoimmune encephalomyelitis (EAE), the induction and progression of the disease are significantly attenuated in mice deficient of the type I IL-1 receptor (IL-1R1) (Schiffenbauer et al., 2000; Sutton et al., 2006) , suggesting IL-1R1 might be a therapeutic target of EAE. Whether this target can be further restricted to IL-1R1 expressed on a specific cell type has not been reported.
The vast majority of IL-1R1 in the brain is found on the endothelial surface, with some IL-1R1 on neurons in the select few brain regions (Ericsson et al., 1995) . Endothelial IL-1R1 has been shown to mediate many IL-1-mediated effects in the CNS (Ching et al., 2007) . The binding of IL-1 to the endothelial IL-1R1 is known to activate endothelial cells and mediates recruitment of leukocytes into the brain through the upregulation of cell adhesion molecules (CAMs) and cytokines (Hubbard and Rothlein, 2000; Ching et al., 2005) . Therefore, endothelial IL-1R1-mediated leukocyte recruitment may be critical in the induction and progression of MS. In this study, we tested the effect of selective knockdown of the expression of endothelial IL-1R1 on the disease course of EAE.
Materials and methods

Transgenic constructs
The transgenic construct is built from a construct containing Tie-2 promoter (2 kb)-rtTA-Tie2 enhancer (10 kb) (Tie2-rtTA) that we built in a previous study (Ching et al., 2007) . In the current study, the rtTA sequence of the Tie2-rtTA is replaced by the sequence of an antisense cDNA of IL-1R1. To this end, cDNA was
